202 related articles for article (PubMed ID: 26372815)
1. Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer.
Patel K; Chowdhury N; Doddapaneni R; Boakye CHA; Godugu C; Singh M
J Pharm Sci; 2015 Dec; 104(12):4417-4426. PubMed ID: 26372815
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-alpha in rats.
Ben Reguiga M; Bonhomme-Faivre L; Farinotti R
J Pharm Pharmacol; 2007 Mar; 59(3):401-8. PubMed ID: 17331344
[TBL] [Abstract][Full Text] [Related]
3. Co-encapsulation of docetaxel and cyclosporin A into SNEDDS to promote oral cancer chemotherapy.
Cui W; Zhao H; Wang C; Chen Y; Luo C; Zhang S; Sun B; He Z
Drug Deliv; 2019 Dec; 26(1):542-550. PubMed ID: 31090467
[TBL] [Abstract][Full Text] [Related]
4. Programmed Co-delivery of tamoxifen and docetaxel using lipid-coated mesoporous silica nanoparticles for overcoming CYP3A4-mediated resistance in triple-negative breast cancer treatment.
Wang Y; Cheng W; Zhu J; He L; Ren W; Bao D; Piao JG
Biomed Pharmacother; 2024 Jan; 170():116084. PubMed ID: 38157645
[TBL] [Abstract][Full Text] [Related]
5. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
6. The efficiency and mechanism of a new absorption enhancer, malic acid, for enhancing the oral bioavailability of docetaxel.
Guo XH; Ding F; Lian X; Cui W; Li Z; Xing Y
Pharm Dev Technol; 2021 Jun; 26(5):592-598. PubMed ID: 33734909
[TBL] [Abstract][Full Text] [Related]
7. Improved Bioavailability and Antitumor Effect of Docetaxel by TPGS Modified Proniosomes: In Vitro and In Vivo Evaluations.
Liu H; Tu L; Zhou Y; Dang Z; Wang L; Du J; Feng J; Hu K
Sci Rep; 2017 Mar; 7():43372. PubMed ID: 28266539
[TBL] [Abstract][Full Text] [Related]
8. Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer.
Doddapaneni R; Patel K; Chowdhury N; Singh M
Exp Cell Res; 2016 Aug; 346(1):65-73. PubMed ID: 27177833
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
10. PEG-PCL based micelle hydrogels as oral docetaxel delivery systems for breast cancer therapy.
Wang Y; Chen L; Tan L; Zhao Q; Luo F; Wei Y; Qian Z
Biomaterials; 2014 Aug; 35(25):6972-85. PubMed ID: 24836952
[TBL] [Abstract][Full Text] [Related]
11. Enhanced antitumor efficacy of bile acid-lipid complex-anchored docetaxel nanoemulsion via oral metronomic scheduling.
Jha SK; Chung JY; Pangeni R; Choi HS; Subedi L; Kweon S; Choi JU; Byun Y; Kim YH; Park JW
J Control Release; 2020 Dec; 328():368-394. PubMed ID: 32890552
[TBL] [Abstract][Full Text] [Related]
12. Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy.
Fan Y; Wang Q; Lin G; Shi Y; Gu Z; Ding T
Acta Biomater; 2017 Oct; 62():257-272. PubMed ID: 28859899
[TBL] [Abstract][Full Text] [Related]
13. Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pre-treatment with curcumin.
Yan YD; Kim DH; Sung JH; Yong CS; Choi HG
Int J Pharm; 2010 Oct; 399(1-2):116-20. PubMed ID: 20727390
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal stability, physicochemical characterization and oral bioavailability of chitosan or its derivative-modified solid lipid nanoparticles loading docetaxel.
Shi LL; Lu J; Cao Y; Liu JY; Zhang XX; Zhang H; Cui JH; Cao QR
Drug Dev Ind Pharm; 2017 May; 43(5):839-846. PubMed ID: 27487431
[TBL] [Abstract][Full Text] [Related]
15. Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model.
Hendrikx JJ; Lagas JS; Song JY; Rosing H; Schellens JH; Beijnen JH; Rottenberg S; Schinkel AH
Int J Cancer; 2016 Feb; 138(3):758-69. PubMed ID: 26297509
[TBL] [Abstract][Full Text] [Related]
16. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer.
Qu MH; Zeng RF; Fang S; Dai QS; Li HP; Long JT
Int J Pharm; 2014 Oct; 474(1-2):112-22. PubMed ID: 25138252
[TBL] [Abstract][Full Text] [Related]
17. Folate-Functionalized Thiomeric Nanoparticles for Enhanced Docetaxel Cytotoxicity and Improved Oral Bioavailability.
Sajjad M; Khan MI; Naveed S; Ijaz S; Qureshi OS; Raza SA; Shahnaz G; Sohail MF
AAPS PharmSciTech; 2019 Jan; 20(2):81. PubMed ID: 30645705
[TBL] [Abstract][Full Text] [Related]
18. Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).
Godugu C; Doddapaneni R; Singh M
Colloids Surf B Biointerfaces; 2017 May; 153():208-219. PubMed ID: 28249200
[TBL] [Abstract][Full Text] [Related]
19. Enhanced oral bioavailability of docetaxel by lecithin nanoparticles: preparation, in vitro, and in vivo evaluation.
Hu K; Cao S; Hu F; Feng J
Int J Nanomedicine; 2012; 7():3537-45. PubMed ID: 22848177
[TBL] [Abstract][Full Text] [Related]
20. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.
Venkatesh PR; Goh E; Zeng P; New LS; Xin L; Pasha MK; Sangthongpitag K; Yeo P; Kantharaj E
Biol Pharm Bull; 2007 May; 30(5):1021-4. PubMed ID: 17473456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
